GlassScriptPhysician profile
Samantha E Lafuente
NPI 1679198873
$875.49
in general payments reported to CMS, 2019-2025
16 companies · $29.97 in 2025
The $29.97 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $54.39 · 2024: $579 · 2025: $29.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $159.30 | 2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $147.76 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $88.60 | 2021-2022 | |
| Abbvie INC. | $77.32 | 2024 | |
| Lundbeck LLC | $65.16 | 2024 | Rexulti |
| Alkermes, INC. | $37.98 | 2024 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.77 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 2024 | Cobenfy, Camzyos |
| Novartis Pharmaceuticals Corporation | $23.64 | 2022 | |
| Amryt Pharma Holdings LTD | $23.46 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.52 | 2024 | |
| Janssen Scientific Affairs, LLC | $19.66 | 2024 | Spravato |
| Abiomed | $19.49 | 2024 | Impella |
| Amgen INC. | $18.02 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Lafuente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.